company background image
PSTV

Plus Therapeutics NasdaqCM:PSTV Stock Report

Last Price

US$1.98

Market Cap

US$8.1m

7D

15.1%

1Y

-66.2%

Updated

04 Dec, 2023

Data

Company Financials +

Plus Therapeutics, Inc.

NasdaqCM:PSTV Stock Report

Mkt Cap: US$8.1m

PSTV Stock Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.

PSTV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Plus Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Plus Therapeutics
Historical stock prices
Current Share PriceUS$1.98
52 Week HighUS$7.20
52 Week LowUS$0.97
Beta0.45
1 Month Change23.75%
3 Month Change-27.47%
1 Year Change-66.15%
3 Year Change-93.53%
5 Year Change-99.18%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Oct 07

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Sep 22

Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02

Jul 21

Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems

Dec 21

Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?

Aug 25
Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?

Plus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trial

Jun 16

Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why

May 11
Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why

Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract

May 04

Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?

Feb 23
Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?

Plus Therapeutics shows positive data for ReSPECT Phase 1 clinical trial in GBM

Nov 19

Shareholder Returns

PSTVUS BiotechsUS Market
7D15.1%3.8%0.9%
1Y-66.2%-5.8%13.6%

Return vs Industry: PSTV underperformed the US Biotechs industry which returned -7.8% over the past year.

Return vs Market: PSTV underperformed the US Market which returned 11.7% over the past year.

Price Volatility

Is PSTV's price volatile compared to industry and market?
PSTV volatility
PSTV Average Weekly Movement23.0%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: PSTV is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: PSTV's weekly volatility has increased from 16% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199617Marc Hedrickhttps://plustherapeutics.com

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.

Plus Therapeutics, Inc. Fundamentals Summary

How do Plus Therapeutics's earnings and revenue compare to its market cap?
PSTV fundamental statistics
Market CapUS$8.14m
Earnings (TTM)-US$15.16m
Revenue (TTM)US$3.75m

2.4x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PSTV income statement (TTM)
RevenueUS$3.75m
Cost of RevenueUS$9.03m
Gross Profit-US$5.28m
Other ExpensesUS$9.88m
Earnings-US$15.16m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.35
Gross Margin-140.84%
Net Profit Margin-404.27%
Debt/Equity Ratio165.8%

How did PSTV perform over the long term?

See historical performance and comparison